SME Central
Home / Moved to Main Board / ANG Lifesciences India

ANG Lifesciences India: IPO, Share Price and Results Since Listing

ANG Lifesciences India moved from BSE SME to the BSE main board. For Q2 FY2027 it reported revenue of INR 20.10 crore (-22.85% on a year earlier) and a loss of INR 2.09 crore.

Key Facts

Moved to
BSE main board (BSE does not publish the date)
Listed on BSE SME
8 September 2017
Symbol
ANG (BSE code 540694)
Latest close
INR 41.17 on 13 November 2026

Results Filed With BSE

Consolidated figures, INR crore. Change compares with the same period a year earlier.

PeriodRevenueChangeProfit after taxEPS (INR)Filed
Q2 FY202720.10-22.85%-2.09-1.59after listing15 November 2026
Q1 FY202715.30-37.82%-4.24-3.24after listing14 August 2026
Q4 FY202623.50+39.70%-1.38-1.07after listing30 May 2026
FY202692.89+0.05%-11.08-8.43after listing30 May 2026
Q3 FY202618.73–-4.75-3.60after listing14 February 2026
Q2 FY202626.05–-2.95-2.24after listing14 November 2025
Q1 FY202624.60–-2.01-1.52after listing14 August 2025
Q4 FY202516.82–-2.06-1.56after listing30 May 2025
FY202592.85–-12.41-9.42after listing30 May 2025

Promoter Holding

Promoter holding has moved from 70.60% on 31 December 2025 to 70.60% on 30 September 2026 (0 percentage points).

As ofPromotersPublic
30 September 202670.60%29.40%
30 June 202670.60%29.40%
31 March 202670.60%29.40%
31 December 202570.60%29.40%

Sources: BSE filings (results XBRL, shareholding pattern, board meetings), BSE daily price files, and IPO records. Prices are not adjusted for bonus issues or splits.